LexBio and Hiteck partner to develop novel drug candidates using AI-driven molecular glue degraders targeting B- and ...
AGNi is different from today’s AI and AGI approaches, geared to maximize the user’s benefit to advance health and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results